PuSH - Publikationsserver des Helmholtz Zentrums München

Low-to-moderate dosed cranial irradiation in young mice induces sex-specific metabolic disturbances later in life.

Diabetes 74, 1775-1786 (2025)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
UNLABELLED: Survivors of childhood cancers who received high doses (40-60 Gy) of cranial irradiation (CI) have increased risks of developing obesity, type 2 diabetes, and metabolic syndrome (MetS). Here, we subjected mice to CI of 0, 0.5, or 2 Gy directed to the hypothalamus to explore the effects of low-to-moderate doses of CI on MetS risks. Despite targeting the hypothalamus as a major metabolic control center, we did not detect hypothalamic astrocyte or microglia activation at 2 or 7 days, or at 3 months post-CI. Indirect calorimetry at 2 months post-CI showed no metabolic alterations between groups, yet female mice subjected to CI were unresponsive to leptin compared with sham. Follow-up monitoring over 2 years revealed accelerated weight gain in the 2-Gy female group and glucose intolerance in both sexes following CI. Insulin sensitivity, plasma insulin, and triglycerides remained unaltered, but both male and female 2-Gy groups showed elevated VLDL and lowered HDL cholesterol levels and aberrant hypothalamic mRNA levels of genes involved in synaptic and neuronal function, neuroinflammation, and endoplasmic reticulum stress. Mortality remained unaffected by all doses of CI. These data strongly suggest a significant risk for developing MetS following low-to-moderate doses of CI, and they support tailored clinical risk assessment and monitoring strategies for patients undergoing CI, especially when the hypothalamus is included. ARTICLE HIGHLIGHTS: High-dose cranial irradiation (CI) during early developmental stages has been linked to metabolic abnormalities in later life, but causal evidence at low-to-moderate doses has been elusive. Monitoring mice for 2 years post-2-Gy CI to the hypothalamus, we found increased risks of leptin resistance, dyslipidemia, glucose intolerance, and weight gain, identifying the hypothalamus as the likely responsible region. Our findings suggest that low-to-moderate doses of CI may be a risk factor for developing metabolic syndrome. Future clinical risk assessment and monitoring strategies are needed for patients undergoing CI of hypothalamic centers governing glucose and energy metabolism.
Impact Factor
Scopus SNIP
Altmetric
7.500
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Long-term Survivors; Hypothalamic Injury; Diabetes-mellitus; Body-weight; Childhood; Cancer; Radiation; Obesity; Diet; Sarcopenia
Sprache englisch
Veröffentlichungsjahr 2025
HGF-Berichtsjahr 2025
ISSN (print) / ISBN 0012-1797
e-ISSN 1939-327X
Zeitschrift Diabetes
Quellenangaben Band: 74, Heft: 10, Seiten: 1775-1786 Artikelnummer: , Supplement: ,
Verlag American Diabetes Association
Verlagsort Alexandria, VA.
Begutachtungsstatus Peer reviewed
POF Topic(s) 30201 - Metabolic Health
30203 - Molecular Targets and Therapies
Forschungsfeld(er) Helmholtz Diabetes Center
Radiation Sciences
PSP-Element(e) G-502294-001
G-501300-001
G-502200-001
G-501391-001
Förderungen Marie Sklodowska-Curie grant
German Research Foundation
European Union
Helmholtz-Israel Cooperation in Personalized Medicine
PubMed ID 40762619
Erfassungsdatum 2025-11-05